BAM
GILD icon

Berkshire Asset Management’s Gilead Sciences GILD Stock Holding History

Berkshire Asset Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,735
Closed -$242K – 274
2026
Q1 		$242K Buy
+1,735
New +$243K 0.01% 239
2018
Q2 		– Sell
-4,610
Closed -$348K – 216
2018
Q1 		$348K Buy
+4,610
New +$366K 0.03% 161
2017
Q2 		– Sell
-3,981
Closed -$270K – 192
2017
Q1 		$270K Buy
+3,981
New +$280K 0.03% 166

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Berkshire Asset Management's GILD Position: Q2 2026 in Review

Berkshire Asset Management sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 1,735 shares — an estimated $242K sold.

Berkshire Asset Management first reported a position in GILD in Q1 2017 and held it in 3 quarters. The position peaked at $348K in Q1 2018. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Berkshire Asset Management reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
  • Berkshire Asset Management sold 1,735 Gilead Sciences shares in Q2 2026, an estimated $242K.
  • Berkshire Asset Management first reported a position in Gilead Sciences in Q1 2017 and held it in 3 quarters.
  • Berkshire Asset Management's Gilead Sciences position peaked at $348K in Q1 2018.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Berkshire Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.